A detailed history of ETF Managers Group, LLC transactions in Arbutus Biopharma Corp stock. As of the latest transaction made, ETF Managers Group, LLC holds 51,963 shares of ABUS stock, worth $182,390. This represents 0.01% of its overall portfolio holdings.

Number of Shares
51,963
Previous 639,973 91.88%
Holding current value
$182,390
Previous $1.49 Million 89.47%
% of portfolio
0.01%
Previous 0.07%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

Apr 17, 2023

SELL
$2.23 - $3.1 $1.31 Million - $1.82 Million
-588,010 Reduced 91.88%
51,963 $157,000
Q4 2022

Mar 23, 2023

BUY
$1.91 - $2.85 $1.14 Million - $1.7 Million
595,723 Added 1346.27%
639,973 $1.49 Million
Q3 2022

Nov 14, 2022

SELL
$1.88 - $2.88 $5,147 - $7,885
-2,738 Reduced 5.83%
44,250 $85,000
Q2 2022

Aug 15, 2022

BUY
$1.98 - $3.17 $11,794 - $18,883
5,957 Added 14.52%
46,988 $127,000
Q1 2022

May 13, 2022

BUY
$2.42 - $3.98 $234 - $386
97 Added 0.24%
41,031 $122,000
Q4 2021

Feb 14, 2022

BUY
$3.11 - $4.61 $14,700 - $21,791
4,727 Added 13.06%
40,934 $159,000
Q3 2021

Nov 15, 2021

BUY
$2.65 - $4.62 $20,553 - $35,832
7,756 Added 27.26%
36,207 $155,000
Q2 2021

Aug 16, 2021

BUY
$2.5 - $3.51 $6,105 - $8,571
2,442 Added 9.39%
28,451 $90,000
Q1 2021

May 17, 2021

SELL
$3.14 - $4.84 $48,010 - $74,003
-15,290 Reduced 37.02%
26,009 $82,000
Q4 2020

Feb 16, 2021

SELL
$2.76 - $4.97 $11,244 - $20,247
-4,074 Reduced 8.98%
41,299 $154,000
Q3 2020

Nov 16, 2020

BUY
$1.75 - $6.2 $43,492 - $154,088
24,853 Added 121.12%
45,373 $144,000
Q2 2020

Aug 14, 2020

BUY
$0.91 - $2.36 $18,673 - $48,427
20,520 New
20,520 $39,000

Others Institutions Holding ABUS

About Arbutus Biopharma Corp


  • Ticker ABUS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 149,951,008
  • Market Cap $526M
  • Description
  • Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...
More about ABUS
Track This Portfolio

Track ETF Managers Group, LLC Portfolio

Follow ETF Managers Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of ETF Managers Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on ETF Managers Group, LLC with notifications on news.